Richard C. Young & CO. LTD. Sells 13,159 Shares of Sanofi (NASDAQ:SNY)

Richard C. Young & CO. LTD. reduced its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 27.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,694 shares of the company's stock after selling 13,159 shares during the quarter. Richard C. Young & CO. LTD.'s holdings in Sanofi were worth $1,999,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Northwest Investment Counselors LLC bought a new position in shares of Sanofi during the 3rd quarter valued at approximately $29,000. POM Investment Strategies LLC bought a new position in shares of Sanofi during the 2nd quarter worth $25,000. Concord Wealth Partners raised its stake in Sanofi by 157.8% in the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company's stock valued at $34,000 after acquiring an additional 363 shares during the period. Arrow Financial Corp bought a new position in Sanofi during the second quarter worth about $35,000. Finally, Fortitude Family Office LLC increased its stake in shares of Sanofi by 708.6% in the third quarter. Fortitude Family Office LLC now owns 752 shares of the company's stock worth $43,000 after purchasing an additional 659 shares in the last quarter. Institutional investors and hedge funds own 10.04% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Citigroup upgraded shares of Sanofi to a "strong-buy" rating in a research note on Tuesday, September 17th. Argus upped their price target on shares of Sanofi from $55.00 to $60.00 and gave the stock a "buy" rating in a report on Friday, July 26th. Finally, StockNews.com downgraded Sanofi from a "strong-buy" rating to a "buy" rating in a research report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $57.50.

Sanofi Trading Up 1.0 %

NASDAQ:SNY traded up $0.50 during midday trading on Monday, reaching $48.47. 878,529 shares of the stock traded hands, compared to its average volume of 2,033,150. The stock has a market capitalization of $123.01 billion, a P/E ratio of 24.47, a PEG ratio of 1.22 and a beta of 0.61. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The company has a fifty day moving average of $54.65 and a 200 day moving average of $52.23.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $1.35. The firm had revenue of $13.44 billion for the quarter, compared to analysts' expectations of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business's revenue was up 12.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.55 earnings per share. On average, research analysts predict that Sanofi will post 4.29 EPS for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.